Ozmosi | Teneligliptin Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Teneligliptin

Alternative Names: teneligliptin, mp-513, mp513, mp 513
Clinical Status: Active
Latest Update: 2025-08-05
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: DPP4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Argentina | India | Italy | Japan | Korea | Philippines

Approved Indications: None

Known Adverse Events: None

Company: Mitsubishi Tanabe
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Teneligliptin

Countries in Clinic: Korea

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Type 2 Diabetes

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05504239

 TERA 304

P3

Completed

Type 2 Diabetes

2024-04-23

16%

2025-01-25

NCT05504226

 TERA 305

P3

Completed

Type 2 Diabetes

2023-11-30

16%

2025-01-28

Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status

Recent News Events

Date

Type

Title

06/18/2024

News Article

 Endocrinology Drugs Market size is set to grow by USD 36.83 billion from 2024-2028, increase in incidence of endocrine disorders to boost the market growth, Technavio

05/10/2024

PubMed

 Reductive N-Alkylation of Amines with Ketones Using Heterogeneous Polysilane-Palladium Catalysts under Continuous-Flow Conditions.

04/15/2024

PubMed

 Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome.

03/01/2024

PubMed

 Evaluation of microalbuminuria in type-2 diabetes mellitus under oral hypoglycemic agents: Association with age, sex, BMI, and renal clearance.

05/22/2023

News Article

 Diabetes Drugs Market Size to Worth Around USD 118 BN by 2032

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions